 Several molecular families of NNRTIs have emerged following screening and evolution of many molecules.Three NNRTI compounds of the first generation have been approved by the FDA for treating HIV-1 infection.Nevirapine was approved in 1996, delavirdine in 1997 and efavirenz in 1998 (table 1).